Published in Chem Biol on April 24, 2009
Exactly the same but different: promiscuity and diversity in the molecular mechanisms of action of the aryl hydrocarbon (dioxin) receptor. Toxicol Sci (2011) 2.48
The homeodomain protein HOXB13 regulates the cellular response to androgens. Mol Cell (2009) 2.07
New concepts in pharmacological efficacy at 7TM receptors: IUPHAR review 2. Br J Pharmacol (2013) 1.43
Minireview: Not picking pockets: nuclear receptor alternate-site modulators (NRAMs). Mol Endocrinol (2009) 1.25
An interdomain interaction of the androgen receptor is required for its aggregation and toxicity in spinal and bulbar muscular atrophy. J Biol Chem (2010) 1.03
Identical gene regulation patterns of T3 and selective thyroid hormone receptor modulator GC-1. Endocrinology (2011) 0.99
A genome-wide RNA interference screen identifies new regulators of androgen receptor function in prostate cancer cells. Genome Res (2013) 0.97
Peroxisome proliferator-activated receptors and cancer: challenges and opportunities. Br J Pharmacol (2011) 0.95
The 2010 Philip S. Portoghese Medicinal Chemistry Lectureship: addressing the "core issue" in the design of estrogen receptor ligands. J Med Chem (2011) 0.95
Minireview: dynamic structures of nuclear hormone receptors: new promises and challenges. Mol Endocrinol (2013) 0.94
Inhibition of prostate cancer cell growth by second-site androgen receptor antagonists. Proc Natl Acad Sci U S A (2009) 0.93
Predictive features of ligand-specific signaling through the estrogen receptor. Mol Syst Biol (2016) 0.85
Mechanism of action of bolandiol (19-nortestosterone-3beta,17beta-diol), a unique anabolic steroid with androgenic, estrogenic, and progestational activities. J Steroid Biochem Mol Biol (2009) 0.82
Nuclear receptors and AMPK: resetting metabolism. Cold Spring Harb Symp Quant Biol (2012) 0.81
ELF3 is a repressor of androgen receptor action in prostate cancer cells. Oncogene (2013) 0.81
Solution formulation development and efficacy of MJC13 in a preclinical model of castration-resistant prostate cancer. Pharm Dev Technol (2014) 0.79
Identification of a Novel Coregulator, SH3YL1, That Interacts With the Androgen Receptor N-Terminus. Mol Endocrinol (2015) 0.79
Safety, Pharmacokinetics and Pharmacologic Effects of the Selective Androgen Receptor Modulator, GSK2881078, in Healthy Men and Postmenopausal Women. Br J Clin Pharmacol (2017) 0.78
Unravelling druggable signalling networks that control F508del-CFTR proteostasis. Elife (2015) 0.78
Research Resource: Androgen Receptor Activity Is Regulated Through the Mobilization of Cell Surface Receptor Networks. Mol Endocrinol (2015) 0.76
Inhibiting androgen receptor nuclear entry in castration-resistant prostate cancer. Nat Chem Biol (2016) 0.75
Chemical approaches to nuclear receptors in metabolism. Sci Signal (2009) 0.75
Androgen receptor antagonism drives cytochrome P450 17A1 inhibitor efficacy in prostate cancer. J Clin Invest (2017) 0.75
Onto-Tools: an ensemble of web-accessible, ontology-based tools for the functional design and interpretation of high-throughput gene expression experiments. Nucleic Acids Res (2004) 12.19
A signature motif in transcriptional co-activators mediates binding to nuclear receptors. Nature (1997) 11.15
The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell (1998) 9.96
Onto-Tools, the toolkit of the modern biologist: Onto-Express, Onto-Compare, Onto-Design and Onto-Translate. Nucleic Acids Res (2003) 9.30
Molecular basis of agonism and antagonism in the oestrogen receptor. Nature (1997) 9.09
Molecular determinants for the tissue specificity of SERMs. Science (2002) 6.20
Two classes of proteins dependent on either the presence or absence of thyroid hormone for interaction with the thyroid hormone receptor. Mol Endocrinol (1995) 3.59
Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Engl J Med (1992) 3.54
Progression of metastatic human prostate cancer to androgen independence in immunodeficient SCID mice. Nat Med (1997) 3.46
Human estrogen receptor transactivational capacity is determined by both cellular and promoter context and mediated by two functionally distinct intramolecular regions. Mol Endocrinol (1994) 2.62
Structural evidence for ligand specificity in the binding domain of the human androgen receptor. Implications for pathogenic gene mutations. J Biol Chem (2000) 2.60
FXXLF and WXXLF sequences mediate the NH2-terminal interaction with the ligand binding domain of the androgen receptor. J Biol Chem (2000) 2.58
Discovery of nonsteroidal androgens. Biochem Biophys Res Commun (1998) 2.21
Dissection of the LXXLL nuclear receptor-coactivator interaction motif using combinatorial peptide libraries: discovery of peptide antagonists of estrogen receptors alpha and beta. Mol Cell Biol (1999) 2.13
Peptide antagonists of the human estrogen receptor. Science (1999) 1.86
HOXB13 induces growth suppression of prostate cancer cells as a repressor of hormone-activated androgen receptor signaling. Cancer Res (2004) 1.83
Analysis of estrogen receptor function in vitro reveals three distinct classes of antiestrogens. Mol Endocrinol (1995) 1.75
Pharmacodynamics of selective androgen receptor modulators. J Pharmacol Exp Ther (2003) 1.73
Cloning and characterization of human prostate coactivator ARA54, a novel protein that associates with the androgen receptor. J Biol Chem (1999) 1.69
A coregulatory role for the TRAP-mediator complex in androgen receptor-mediated gene expression. J Biol Chem (2002) 1.66
Regulation of androgen receptor signaling by PTEN (phosphatase and tensin homolog deleted on chromosome 10) tumor suppressor through distinct mechanisms in prostate cancer cells. Mol Endocrinol (2004) 1.62
Synthesis and biological activity of a novel series of nonsteroidal, peripherally selective androgen receptor antagonists derived from 1,2-dihydropyridono[5,6-g]quinolines. J Med Chem (1998) 1.62
The FXXLF motif mediates androgen receptor-specific interactions with coregulators. J Biol Chem (2002) 1.57
Cell cycle progression stimulated by tamoxifen-bound estrogen receptor-alpha and promoter-specific effects in breast cancer cells deficient in N-CoR and SMRT. Mol Endocrinol (2005) 1.55
Structural basis for an unexpected mode of SERM-mediated ER antagonism. Mol Cell (2005) 1.50
Selective androgen receptor modulators (SARMs): a novel approach to androgen therapy for the new millennium. J Clin Endocrinol Metab (1999) 1.47
Circumventing tamoxifen resistance in breast cancers using antiestrogens that induce unique conformational changes in the estrogen receptor. Cancer Res (2001) 1.38
Distinguishing androgen receptor agonists and antagonists: distinct mechanisms of activation by medroxyprogesterone acetate and dihydrotestosterone. Mol Endocrinol (1999) 1.32
The linkage of Kennedy's neuron disease to ARA24, the first identified androgen receptor polyglutamine region-associated coactivator. J Biol Chem (1999) 1.30
Expanding the therapeutic use of androgens via selective androgen receptor modulators (SARMs). Drug Discov Today (2007) 1.18
Androgen receptor-cofactor interactions as targets for new drug discovery. Trends Pharmacol Sci (2005) 1.16
Raloxifene, tamoxifen, nafoxidine, or estrogen effects on reproductive and nonreproductive tissues in ovariectomized rats. FASEB J (1996) 1.14
Interaction of the human androgen receptor transactivation function with the general transcription factor TFIIF. Proc Natl Acad Sci U S A (1997) 1.14
Development of peptide antagonists for the androgen receptor using combinatorial peptide phage display. Mol Endocrinol (2005) 1.14
Pharmacological and x-ray structural characterization of a novel selective androgen receptor modulator: potent hyperanabolic stimulation of skeletal muscle with hypostimulation of prostate in rats. Endocrinology (2006) 1.13
Linking ligand-induced alterations in androgen receptor structure to differential gene expression: a first step in the rational design of selective androgen receptor modulators. Mol Endocrinol (2006) 1.11
Supervillin associates with androgen receptor and modulates its transcriptional activity. Proc Natl Acad Sci U S A (2002) 1.10
The NH(2)-terminal and carboxyl-terminal interaction in the human androgen receptor. Mol Genet Metab (2002) 1.09
Modulation of androgen receptor transactivation by gelsolin: a newly identified androgen receptor coregulator. Cancer Res (2003) 1.05
Analysis of androgen receptor-DNA interactions with receptor proteins produced in insect cells. J Biol Chem (1994) 1.03
An orally active selective androgen receptor modulator is efficacious on bone, muscle, and sex function with reduced impact on prostate. Endocrinology (2006) 1.02
Evaluation of ligand-dependent changes in AR structure using peptide probes. Mol Endocrinol (2002) 1.02
Discovery of novel nuclear receptor modulating ligands: an integral role for peptide interaction profiling. Drug Discov Today (2004) 1.00
Selective androgen receptor modulators in drug discovery: medicinal chemistry and therapeutic potential. Curr Top Med Chem (2006) 0.97
Pharmacological uncoupling of androgen receptor-mediated prostate cancer cell proliferation and prostate-specific antigen secretion. Cancer Res (2003) 0.97
Single-step purification of full-length human androgen receptor. Nucl Recept Signal (2005) 0.93
Elucidation of the molecular mechanism of action of selective estrogen receptor modulators. Am J Cardiol (2002) 0.87
Structure of the ligand-binding domain (LBD) of human androgen receptor in complex with a selective modulator LGD2226. Acta Crystallogr Sect F Struct Biol Cryst Commun (2006) 0.83
Effects of raloxifene in postmenopausal women. N Engl J Med (1998) 0.77
Multiple loci identified in a genome-wide association study of prostate cancer. Nat Genet (2008) 17.65
Detectable clonal mosaicism and its relationship to aging and cancer. Nat Genet (2012) 3.69
Structural analyses reveal phosphatidyl inositols as ligands for the NR5 orphan receptors SF-1 and LRH-1. Cell (2005) 3.29
Evaluation of registration methods on thoracic CT: the EMPIRE10 challenge. IEEE Trans Med Imaging (2011) 2.24
The homeodomain protein HOXB13 regulates the cellular response to androgens. Mol Cell (2009) 2.07
Estrogen-related receptor-α is a metabolic regulator of effector T-cell activation and differentiation. Proc Natl Acad Sci U S A (2011) 1.86
Development of a small-molecule serum- and glucocorticoid-regulated kinase-1 antagonist and its evaluation as a prostate cancer therapeutic. Cancer Res (2008) 1.85
Leptin and insulin stimulation of signalling pathways in arcuate nucleus neurones: PI3K dependent actin reorganization and KATP channel activation. BMC Neurosci (2004) 1.81
Standardized evaluation methodology and reference database for evaluating coronary artery centerline extraction algorithms. Med Image Anal (2009) 1.58
A negative coregulator for the human ER. Mol Endocrinol (2002) 1.49
Estrogen-related receptor alpha is critical for the growth of estrogen receptor-negative breast cancer. Cancer Res (2008) 1.42
The metabolic regulator ERRα, a downstream target of HER2/IGF-1R, as a therapeutic target in breast cancer. Cancer Cell (2011) 1.37
Improved imputation of common and uncommon SNPs with a new reference set. Nat Genet (2011) 1.34
Genome-wide association study identifies multiple loci associated with bladder cancer risk. Hum Mol Genet (2013) 1.34
Selective LXXLL peptides antagonize transcriptional activation by the retinoid-related orphan receptor RORgamma. Biochem Biophys Res Commun (2004) 1.30
Ligand-specific dynamics of the androgen receptor at its response element in living cells. Mol Cell Biol (2006) 1.28
WNT11 expression is induced by estrogen-related receptor alpha and beta-catenin and acts in an autocrine manner to increase cancer cell migration. Cancer Res (2010) 1.19
Receptor-selective coactivators as tools to define the biology of specific receptor-coactivator pairs. Mol Cell (2006) 1.18
Activation of the aryl-hydrocarbon receptor inhibits invasive and metastatic features of human breast cancer cells and promotes breast cancer cell differentiation. Mol Endocrinol (2009) 1.16
Research resource: Transcriptional profiling in a cellular model of breast cancer reveals functional and mechanistic differences between clinically relevant SERM and between SERM/estrogen complexes. Mol Endocrinol (2012) 1.04
ERRgamma regulates cardiac, gastric, and renal potassium homeostasis. Mol Endocrinol (2009) 1.02
Definition of the molecular and cellular mechanisms underlying the tissue-selective agonist/antagonist activities of selective estrogen receptor modulators. Recent Prog Horm Res (2002) 1.01
Regulation of aryl hydrocarbon receptor function by selective estrogen receptor modulators. Mol Endocrinol (2009) 1.01
Organochlorine-mediated potentiation of the general coactivator p300 through p38 mitogen-activated protein kinase. Carcinogenesis (2008) 1.00
The molecular genetics of the human I locus and molecular background explain the partial association of the adult i phenotype with congenital cataracts. Blood (2002) 0.97
Pharmacological uncoupling of androgen receptor-mediated prostate cancer cell proliferation and prostate-specific antigen secretion. Cancer Res (2003) 0.97
Single-step purification of full-length human androgen receptor. Nucl Recept Signal (2005) 0.93
Inhibition of prostate cancer cell growth by second-site androgen receptor antagonists. Proc Natl Acad Sci U S A (2009) 0.93
Research resource: nuclear receptor atlas of human retinal pigment epithelial cells: potential relevance to age-related macular degeneration. Mol Endocrinol (2011) 0.91
Effects of birth ball exercise on pain and self-efficacy during childbirth: a randomised controlled trial in Taiwan. Midwifery (2011) 0.90
Fasting-induced hepatic production of DHEA is regulated by PGC-1alpha, ERRalpha, and HNF4alpha. Mol Endocrinol (2009) 0.88
Genotype polymorphisms of GGCX, NQO1, and VKORC1 genes associated with risk susceptibility in patients with large-artery atherosclerotic stroke. Clin Chim Acta (2010) 0.86
Molecular genetic analysis for the B(3) allele. Blood (2002) 0.84
Mechanisms of progesterone receptor inhibition of inflammatory responses in cellular models of breast cancer. Mol Endocrinol (2010) 0.84
Purification and characterization of recombinant human mineralocorticoid receptor. Mol Cell Endocrinol (2008) 0.83
The vitamin D receptor interacts preferentially with DRIP205-like LxxLL motifs. Arch Biochem Biophys (2007) 0.83
Complexities of holistic community-based participatory research for a low income, multi-ethnic population exposed to multiple built-environment stressors in Worcester, Massachusetts. Environ Res (2009) 0.82
Synthetic LXXLL peptide antagonize 1,25-dihydroxyvitamin D3-dependent transcription. J Cell Biochem (2003) 0.81
alpha-Naphthoflavone, a potent antiplatelet flavonoid, is mediated through inhibition of phospholipase C activity and stimulation of cyclic GMP formation. J Agric Food Chem (2005) 0.80
Aryl hydrocarbon receptor knock-out exacerbates choroidal neovascularization via multiple pathogenic pathways. J Pathol (2014) 0.78
Inhibition of 1,25-dihydroxyvitamin D3-dependent transcription by synthetic LXXLL peptide antagonists that target the activation domains of the vitamin D and retinoid X receptors. J Bone Miner Res (2002) 0.78
On-chip ligation of multiplexing probe-pairs for identifying point mutations out of dense SNP loci. Biosens Bioelectron (2008) 0.78
Enzyme catalytic promiscuity: The papain-catalyzed Knoevenagel reaction. Biochimie (2011) 0.78
Exploring interhemispheric collaboration in older compared to younger adults. Brain Cogn (2009) 0.77
The transdiagnostic nature of metacognitions in women with eating disorders. Eat Disord (2014) 0.77
3,3'-Disubstituted bipolar biphenyls as inhibitors of nuclear receptor coactivator binding. Bioorg Med Chem Lett (2012) 0.77
Generation and characterization of human steroidogenic factor 1 LBD crystals with and without bound cofactor peptide. Endocr Res (2004) 0.76
Rapid transformation of protein-caged nanomaterials into microbubbles as bimodal imaging agents. ACS Nano (2012) 0.76
Low-cost preparation of photoluminescent carbon nanodots and application as peroxidase mimetics in colorimetric detection of H2O2 and glucose. J Nanosci Nanotechnol (2013) 0.75
[An experience applying Gua-Sha to help a parturient women with breast fullness]. Hu Li Za Zhi (2008) 0.75
Multifunctional Iron Oxide Nanoflake/Graphene Composites Derived from Mechanochemical Synthesis for Enhanced Lithium Storage and Electrocatalysis. ACS Appl Mater Interfaces (2015) 0.75
A hierarchical Zn2Mo3O8 nanodots-porous carbon composite as a superior anode for lithium-ion batteries. Chem Commun (Camb) (2016) 0.75
Nanoporous gold film: fabrication and role as a catalytic reactor. Dalton Trans (2015) 0.75
Labeling Proteins Inside Living Cells Using External Fluorophores for Fluorescence Microscopy. Elife (2017) 0.75